Table 1.
Patient Characteristics
| Table 1: Baseline Patient Characteristics | |||||
|---|---|---|---|---|---|
| Magnesium 1200 mg/d (N=91) |
Magnesium 800 mg/d (N=93) |
Placebo (N=91) |
Total (N=275) |
P value | |
| Characteristic | N (%) | N (%) | N (%) | N (%) | |
| Age, years | 1.001 | ||||
| 18–49 | 15 (17%) | 15 (16%) | 15 (17%) | 45 (16%) | |
| >=50 | 76 (83%) | 78 (84%) | 76 (83%) | 230 (84%) | |
| Race | 0.522 | ||||
| White | 86 (95%) | 89 (96%) | 88 (97%) | 263 (96%) | |
| Black or African American | 4 (4%) | 2 (2%) | 3 (3%) | 9 (3%) | |
| Asian | 1 (1%) | 0 (0%) | 0 (0%) | 1 (0.4%) | |
| Not reported | 0 (0%) | 2 (2%) | 0 (0%) | 2 (1%) | |
| Current anti-estrogen therapy | 0.881 | ||||
| None | 15 (17%) | 15 (16%) | 15 (17%) | 45 (16%) | |
| Aromatase Inhibitor | 43 (47%) | 41 (44%) | 42 (46%) | 126 (46%) | |
| Tamoxifen | 33 (36%) | 37 (40%) | 34 (36%) | 104 (38%) | |
| Reported daily frequency of hot flashes | 0.052 | ||||
| 4–9 | 53 (58%) | 47 (50%) | 62 (68%) | 162 (59%) | |
| 10+ | 38 (42%) | 46 (50%) | 29 (32%) | 113 (41%) | |
| Use of oral calcium | 49 (54%) | 49 (53%) | 48 (53%) | 146 (53%) | 0.981 |
| Use of vitamin D | 57 (63%) | 56 (60%) | 57 (63%) | 170 (62%) | 0.931 |
| Baseline Serum Magnesium (mg/dL) | 0.183 | ||||
| N | 90 | 90 | 91 | 271 | |
| Mean (SD) | 2.0 (0.2) | 2.1 (0.2) | 2.0 (0.2) | 2.0 (0.2) | |
| Median | 2.0 | 2.1 | 2.0 | 2.0 | |
P-values calculated using
1
Chi-Square,
2
Fisher Exact, or
3
Kruskal Wallis methods